India’s Biotech Moment: Can Northeast India Build Its Next Bioeconomy?
Northeast Renaissance Series
BIO-NIVESH, BioE3 and the ₹1 lakh crore RDI push are opening a new investment window.
I have travelled to some of the remotest parts of the Northeast over three decades. I have seen places with barely any roads, where a 140-kilometre journey could take 14 hours. Even so, I have always believed this region holds enough resources to become one of the most prosperous in the world.
The forests, rivers, bamboo, medicinal plants, food crops, wildlife and microorganisms have always been here. So has the traditional knowledge built by generations who lived with these resources and understood them deeply. Modern science is only now starting to study that knowledge systematically.
Yet this abundance has rarely translated into prosperity. The Northeast has mostly supplied raw materials, while the higher-value work — processing, branding, intellectual property, manufacturing — happened elsewhere. In short, the region held the resource, but somebody else captured the value.
That equation could now change.https://www.pib.gov.in/PressReleaseDetail.aspx?PRID=2306405®=3&lang=1
India is entering a phase where biology itself becomes an industrial resource. The Northeast may be unusually well placed to benefit.
On September 3, 2026, the Government of India launched BIO-NIVESH, a platform to connect biotechnology innovators with investors and channel private capital into scale-up and commercialisation. Its first edition brought together 20 biotech and deep-tech startups with roughly 50 investors.
BIO-NIVESH matters for more than a Delhi meeting. It signals a shift in India’s economic thinking: biotechnology is becoming an engine of industrial growth, not just a research or healthcare field.
For the Northeast, that raises a bigger question. Can a region long rich in biological resources finally become rich in biological value?
Why India’s Biotechnology Economy Is Entering a New Phase
India’s biotechnology story has shifted fast over the past decade.
The India BioEconomy Report 2026 puts India’s BioEconomy at US$195.3 billion in 2025 — 18% growth over 2024, and 4.8% of national GDP. The country now counts 11,855 biotech startups, far beyond its earlier base of research institutions and pharma firms.
The mix matters too. BioIndustrial activity reached about US$90.2 billion, BioPharma US$64.5 billion, BioServices US$26 billion and BioAgri US$14.6 billion in 2025. BioIndustrial and BioPharma together make up nearly three-quarters of the total. So the sector is shifting toward manufacturing and commercial production, not just services or lab research.
The ambition ahead is larger still. A July 2026 NITI Aayog roadmap projects India’s BioEconomy at US$392 billion by 2030, US$691 billion by 2035 and US$2.6 trillion by 2047. That vision includes over 30 million high-value jobs, plus a bigger role for AI-enabled biotechnology and next-generation biomanufacturing.https://www.niti.gov.in/sites/default/files/2026-07/Roadmap-for-Building-India-as-a-Leading-Bioeconomy-Powerhouse.pdf
A new financing architecture is emerging alongside this ambition.
The Government’s ₹1 lakh crore Research, Development and Innovation Fund, launched in November 2025, backs deep-tech and high-impact indigenous innovation. BIRAC now serves as a Second-Level Fund Manager for biotechnology, and the BIRAC-RDIF mechanism helps move projects from roughly Technology Readiness Level 4 to Level 9. Eligible startups and industry can receive ₹5 crore to ₹200 crore, covering up to half the project cost.
This matters because biotechnology faces a financing problem unlike software’s.
A promising biological technology can take years to validate, scale, regulate and commercialise. Between the lab and the factory sits a difficult middle ground: pilot facilities, process engineering, intellectual property, quality systems, regulatory approval and patient capital. India is now trying to build that bridge. BIO-NIVESH is one more piece — bringing investors closer to companies at the point where scientific promise must become commercial reality.
A Global Opportunity Already Taking Shape
The scale of the global opportunity explains why this shift matters.
Global estimates vary widely, because biotechnology spans pharmaceuticals, agriculture, industrial chemicals, research services and computational biology. So it helps to look at individual sectors that overlap with India’s emerging BioEconomy, rather than one combined figure.
The global biopharmaceutical market stood at US$453.7 billion in 2025 and should reach about US$921.5 billion by 2034.
Agricultural biotechnology stood at roughly US$161.5 billion in 2025, heading toward US$212.6 billion by 2030.
The more specialised bio-based platform chemicals market reached US$15.4 billion in 2025, projected to hit US$24.8 billion by 2033. These chemicals can become building blocks for materials, polymers, food ingredients, pharmaceuticals and other industrial products.
Then there’s the computational layer. Global bioinformatics stood at US$20.1 billion in 2025 and should reach US$63.7 billion by 2033, as genomics, drug discovery, data science and AI increasingly intersect.
These figures overlap, so they shouldn’t simply be added together. But together, they show something clear: biotechnology is becoming a platform economy that touches medicine, agriculture, food, chemicals, materials, environmental solutions and computing. That expands the potential opportunity for a region like the Northeast.
Why the Northeast Could Matter
The Northeast has heard the biodiversity argument many times.
Its forests are rich, and its agricultural systems are diverse. Medicinal and aromatic plants here are distinctive, and bamboo resources are substantial. Rivers, wetlands and ecosystems across the region hold biological resources still only partially understood. On top of this, generations of traditional knowledge about plants, food, agriculture and natural materials can offer valuable leads for modern research — provided researchers study it ethically and scientifically.
But biodiversity alone does not create prosperity. The economic opportunity begins only when biological resources connect to science, processing, intellectual property, manufacturing and markets.https://thequantiq.com/agarwood-industry-assam-global-fragrance-opportunity/
Take a medicinal plant. Sellers can trade it as a raw herb, or scientists can identify, standardise and validate its active compounds, then turn them into pharmaceutical, nutraceutical or cosmetic ingredients. Likewise, agricultural residues can stay waste, or producers can turn them into feedstock for bio-based chemicals, materials, enzymes or fermentation. A traditional food can remain a local speciality, or it can grow into a functional ingredient or a globally marketed nutrition product. The resource stays the same. The value changes only when knowledge gets added. That is the central idea behind the Northeast’s emerging bioeconomy.
The Northeast Is Already Entering the BioE3 Framework
The region is not starting from zero.
The Government’s BioE3 policy — Biotechnology for Economy, Environment and Employment — covers six areas: bio-based chemicals, biopolymers, APIs and enzymes; smart proteins and functional foods; precision biotherapeutics; climate-resilient agriculture; carbon capture and utilisation; and emerging marine and space applications.
For the Northeast specifically, 10% of the BioE3 Biomanufacturing and Biofoundry budget has been earmarked for the region. The Department of Biotechnology is also building Centre-State partnerships through State BioE3 Cells, already notified in Assam and Sikkim.
Concrete work is already underway. In Sikkim, BioE3-linked projects target pests and pathogens affecting large cardamom, alongside efforts to develop disease-tolerant varieties. In Assam, projects focus on carbon capture, utilisation and microalgae applications.
The government reports that BioE3 implementation had mobilised ₹602.09 crore in private-sector investment commitments by August 2026. That figure reflects commitments, not spending — but it signals private capital starting to flow into the biomanufacturing ecosystem.
For the Northeast, this moves the conversation beyond simply protecting biological resources. It opens the door to using science on regional problems, then turning solutions into scalable businesses.
Opportunity Snapshot
The numbers below show the scale of industries Northeast India could tap into. Global figures come from separate market studies with different definitions, so they should not be added together. India’s figures come from the India BioEconomy Report 2026 and the July 2026 NITI Aayog roadmap
| Opportunity | Global Market Potential | India: Current / Projected Scale | Possible Northeast Entry Points |
| BioEconomy | Broad global estimates vary considerably by definition | US$195.3B / ~₹18.5 lakh crore in 2025 → US$691B / ~₹65.3 lakh crore by 2035 | Cross-sector bioeconomy |
| Biopharma | US$453.7B in 2025 → US$921.5B by 2034 | US$64.5B / ~₹6.1 lakh crore in 2025 → US$228B / ~₹21.5 lakh crore by 2035 | Biologics, biosimilars, fermentation, botanical products |
| BioIndustrial | Bio-based platform chemicals: US$15.4B in 2025 → US$24.8B by 2033 | US$90.2B / ~₹8.5 lakh crore in 2025 → US$318B / ~₹30.1 lakh crore by 2035 | Bio-based chemicals, enzymes, biopolymers, biomass |
| BioAgriculture | US$161.5B in 2025 → US$212.6B by 2030 | US$14.6B / ~₹1.4 lakh crore in 2025 → US$90B / ~₹8.5 lakh crore by 2035 | Biofertilisers, biopesticides, resilient crops, microbial solutions |
| BioIT / Research | Bioinformatics: US$20.1B in 2025 → US$63.7B by 2033 | US$26B / ~₹2.5 lakh crore in 2025 → US$55B / ~₹5.2 lakh crore by 2035 | Bio-AI, genomics, bioinformatics, computational biology |
| Long-term Indian BioEconomy | — | US$2.6T / ~₹245.7 lakh crore by 2047 | Opportunity across the value chain |
Rupee equivalents are approximate, using roughly ₹94.5 per US$1 for perspective, not as official valuations. NITI Aayog’s sector projections rest on ABLE estimates and envisaged future potential — read them as strategic projections, not guaranteed outcomes.
The significance here isn’t that Northeast India will build a US$691-billion economy of its own. It won’t.
The real opportunity is narrower and more practical: securing a meaningful position in select segments of a fast-growing Indian and global bioeconomy — specialised ingredients, agricultural biotechnology, bio-based materials, environmental biotechnology, research services, bio-AI, or eventually biomanufacturing. The real question is whether the region can capture more value from resources it already holds.
Why the Northeast Has a Strategic Edge
The Northeast’s biggest advantage isn’t the sheer quantity of its biodiversity. It’s the distinctiveness of that biodiversity, and the range of environments producing it.
Many local crops, plants, food resources and biological materials carry strong geographic and cultural roots. That becomes commercially valuable once scientific validation, traceability, intellectual property and quality standards attach to origin.
The region also offers something often overlooked: a living laboratory of hard problems. Crop diseases, climate variability, tough terrain, food preservation and biomass utilisation aren’t abstract challenges here — they’re everyday life. That gives researchers real problems to solve, not hypothetical ones.https://thequantiq.com/natural-colours-green-textile-chemistry-northeast-india/
This flips the usual innovation model. Instead of building a technology elsewhere and later hunting for a Northeast application, researchers can start with problems rooted here and build solutions that later serve other regions facing similar conditions. There’s a human dimension too. A working bioeconomy needs scientists, technicians, engineers, data specialists, manufacturing professionals, regulators and entrepreneurs. Done right, it gives young people real reasons to stay, return, and build in the Northeast.
Turning Resources Into an Industry
The Northeast should not confuse holding biological resources with running a biotechnology industry. Resources are simply the starting point — competitive advantage comes from knowing how to transform them.
That transformation needs scientific databases, laboratories, extraction and fermentation technology, process engineering, quality standards, IP protection, regulatory expertise, pilot-scale facilities, and companies able to reach markets beyond the region.
National policy is starting to build that bridge. BIRAC-RDIF supports the journey from validation to commercialisation. BioE3 is developing Biofoundries, Biomanufacturing Hubs and Bio-AI infrastructure. BIO-NIVESH links this innovation to private investment.
Picture the ladder this can create. A plant becomes an extract. The extract becomes an ingredient, then a formulation, then a finished product. The process behind it becomes intellectual property. The company behind it can become a global supplier. Each step up this ladder keeps more value — and more jobs — inside the region.
But a handful of grants or government facilities won’t build this ladder alone. The sector needs long development cycles, specialised infrastructure, regulatory support, patient capital, and entrepreneurs who understand both science and markets.
That means stronger links between universities, research institutes, state governments, startups, industry and investors. Researchers need paths into entrepreneurship. Entrepreneurs need infrastructure to scale beyond the lab. Investors need confidence that the region can deliver talent, governance and market access.https://thequantiq.com/medicinal-plants-botanical-extract-industry-northeast-india/
Companies emerging from the region must also think globally from day one. A technology developed in Assam, Sikkim or Meghalaya doesn’t have to stay local. If the science, IP and manufacturing economics hold up, the Northeast can be where a technology is born while the world becomes its market. BIO-NIVESH could help close that gap. The government frames it as an ongoing platform, not a one-off event, with future editions meant to widen the bridge between innovators and investors. For a region where specialised capital has long been scarce, that connection matters.
The Quantiq Assessment
India’s biotechnology moment is no longer a distant promise. The country already runs a US$195.3-billion BioEconomy with nearly 12,000 biotech startups, and NITI Aayog now projects US$691 billion by 2035 and US$2.6 trillion by 2047.
The financing architecture is catching up. The ₹1 lakh crore RDI Fund, BIRAC-RDIF, BioE3 and BIO-NIVESH together aim to move biotechnology from research toward scale, manufacturing and markets.
The Northeast brings something equally important: the biological starting material. Its forests, plants, crops, microorganisms and ecological diversity offer a resource base few other Indian regions can match. What happens next depends on the region, not the resource.
The real opportunity lies in building — universities working with industry, researchers becoming entrepreneurs, investors understanding scientific risk, and young people finding careers without leaving home.
The policy window is open. But policy alone won’t create the renaissance. Investment brings factories. Ecosystems bring prosperity. Factories create jobs — but ecosystems create companies, research capability, intellectual property, skilled talent and generations of economic activity. If the Northeast builds that ecosystem, its biological wealth can finally deliver the prosperity its abundance has long promised.https://thequantiq.com/kaji-nemu-citrus-bioeconomy-northeast-india/
